| Sandhya Thakallapali, MD | |
|
319 W Landis Ave, Vineland, NJ 08360-8101 | |
| (856) 451-4700 | |
| (856) 451-8685 |
| Full Name | Sandhya Thakallapali |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 23 Years |
| Location | 319 W Landis Ave, Vineland, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710128046 | NPI | - | NPPES |
| PENDING | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25MA08538300 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Frederick Health Hospital | Frederick, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Medicine Physicians Of Maryland Pc | 8729138003 | 64 |
News Archive
1-800-Oncologist, Inc. announced today the launch of its Contributing Expert program for oncology and radiology specialists. Members of 1-800-Oncologist's national Contributing Expert network are key opinion leaders in the cancer field that help translate medical news into information patients can understand and act upon.
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn?s disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents.
The larvae of the roundworm Heligmosomoides polygyrus bakeri (Hpb) need a very special environment in order to survive: They have to invade the mucosal layer of the intestine in rodents, the only place where they can then develop into adult worms capable of reproduction.
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
› Verified 6 days ago
| Entity Name | Hospitalist Medicine Physicians Of Maryland Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992945471 PECOS PAC ID: 8729138003 Enrollment ID: O20120223000194 |
News Archive
1-800-Oncologist, Inc. announced today the launch of its Contributing Expert program for oncology and radiology specialists. Members of 1-800-Oncologist's national Contributing Expert network are key opinion leaders in the cancer field that help translate medical news into information patients can understand and act upon.
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn?s disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents.
The larvae of the roundworm Heligmosomoides polygyrus bakeri (Hpb) need a very special environment in order to survive: They have to invade the mucosal layer of the intestine in rodents, the only place where they can then develop into adult worms capable of reproduction.
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sandhya Thakallapali, MD 53 S Laurel St, Floor 2, Bridgeton, NJ 08302-1946 Ph: (856) 451-4700 | Sandhya Thakallapali, MD 319 W Landis Ave, Vineland, NJ 08360-8101 Ph: (856) 451-4700 |
News Archive
1-800-Oncologist, Inc. announced today the launch of its Contributing Expert program for oncology and radiology specialists. Members of 1-800-Oncologist's national Contributing Expert network are key opinion leaders in the cancer field that help translate medical news into information patients can understand and act upon.
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn?s disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents.
The larvae of the roundworm Heligmosomoides polygyrus bakeri (Hpb) need a very special environment in order to survive: They have to invade the mucosal layer of the intestine in rodents, the only place where they can then develop into adult worms capable of reproduction.
Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.
› Verified 6 days ago
Dr. Nicole Christina Zucconi, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1505 W Sherman Ave, Vineland, NJ 08360 Phone: 856-641-8000 | |
Elsie Hobeika, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1505 W Sherman Ave, Vineland, NJ 08360 Phone: 856-641-8000 | |
Sandra Mason, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1505 W Sherman Ave, Vineland, NJ 08360 Phone: 856-641-7675 | |
Jacqueline Rounds, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1505 W. Sherman Avenue, Vineland, NJ 08360 Phone: 856-641-8000 | |
Alexander Antonenko, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 319 Landis Avenue, Vineland, NJ 08360 Phone: 856-451-4700 Fax: 856-451-8685 | |
Raghuraj S Tomar, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2815 E Chestnut Ave, Vineland, NJ 08361 Phone: 856-696-9697 Fax: 856-696-9698 | |
Dr. Taner D Ulke, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1505 W Sherman Ave, Vineland, NJ 08360 Phone: 856-641-8000 |